About us
Who we are
Our strategy
How we are funded
Our people
Governance and structure
Reports and statements
Our impact
Suppliers
Our strategy
Our strategy
Neurodegeneration
Respiratory health
Working with us
Support for MRC researchers
Helping charities
Our partners
Available technologies
Advise & Connect: Covid-19
Funding
LifeArc Ventures
Rare disease research funding
Development Gap Fund
Current funding opportunities
Capabilities
Drug discovery
Antibody humanisation
IP management and technology transfer
Diagnostics development
Careers
Working at LifeArc
Our culture
Benefits and rewards
Students and fellows
How to apply
Job vacancies
News
Latest news
Case studies
Reports and publications
Newsletter
Media contacts
Biotherapeutics
Catch up with the latest news and developments from LifeArc
£1 million awarded to develop cutting-edge therapies for motor neuron disease
2022, an excellent & productive year for
@LifeArcVentures
👇Check out the team highlights below and be sure to sta…
https://t.co/kJa4ZoMopA
Filter by:
All
News Releases
Articles & blogs
Ventures Funding
15 August 2022
GalR2 agonists for the Treatment of Pain
15 August 2022
Beta amyloid-targeted therapeutic antibody
15 August 2022
Anti Plexin B1 antibody for the treatment of Multiple Sclerosis
15 August 2022
Anti Plexin B1 antibody for the treatment of Osteoporosis
15 August 2022
Anti-netrin 1 human Ab for the treatment of atherosclerosis
My Interest
Academic Scientist
Pharma/Biotech
Medical Charity
MRC Scientist
Research Organisation